Glioblastoma Multiforme Therapeutics Market Research Report Recently Published by MarketPublishers.com18 Oct 2011 • by Natalie Aster
LONDON - Glioblastoma multiforme (GBM) is considered to be the most frequently met malignant brain tumor. Over two thirds of GBM cases are found amid people above 50. The therapy depends on such factors as the tumor nature, its growth and location. Well-timed measures aimed at the GMB treatment are essential, as only a half of patients achieve recovery. The global GBM market amounted to USD 370 million last year and is forecast to reach about USD 450 million in six years.
The new market research report “Glioblastoma Multiforme (GBM) Therapeutics - Pipeline Assessment and Market Forecasts to 2018” elaborated by GlobalData provides a comprehensive analyses of seven key GBM markets - US, Germany, Italy, Spain, UK, Japan and France. It focuses on the market data within 2005-2010, reveals the present situation and illustrates how the GBM market is set to develop through 2018. The report delves into the tumor clinical presentation and its characteristics. The study offers pipeline analysis data, information on pipeline candidates by classes and overview of most prominent market players. Key industry drivers, restraints and challenges can also be found. Besides, the research examines recent licensing and partnership deals.
Title: Glioblastoma Multiforme (GBM) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Published: September, 2011
Price: US$ 3,500
Reports on other therapeutic and diagnostic markets are also available:
- Influenza Vaccines Therapeutics - Pipeline Assessment and Market Forecasts to 2018
- Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018
- Ophthalmic Diagnostic Equipment - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
- Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018
More new market reports by the publisher can be found at GlobalData page.
The Market Publishers, Ltd.
Mrs. Tanya Rezler
Tel: +44 208 123 2220
Fax: +44 207 900 3970